Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from MRNA

Stock Market Today: Stocks Are Mixed Ahead of the Fed

Two of the three main equity indexes closed higher on the first day of the final Fed Week of 2024.

Kiplinger

Is Moderna Stock Underperforming the Dow?

Moderna has significantly underperformed the Dow over the past year, and analysts are cautious about the stock’s prospects.

Barchart

2 Vaccine Stocks to Buy on the Dip

Given the cutting-edge pipeline for these two vaccine companies, double-digit slumps in these stocks present a compelling entry point for investors.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Moderna Stock Outlook: Is Wall Street Bullish or Bearish?

Moderna has underperformed the broader market and its peers over the past year, and Wall Street analysts are cautious about the stock’s prospects.

Barchart

Stocks Extend Post-Election Gains Ahead of the FOMC Meeting

The S&P 500 Index ($SPX ) (SPY ) today is up +0.36%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.11%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.84%. Stocks today are moderately higher, with the S&P 500, the Dow Jones Industrials, and...

Barchart

Earnings Preview: What to Expect From Moderna's Report

Moderna is all set to release its fiscal third-quarter earnings next month, and analysts project its loss to rise in double digits.

Barchart

Moderna Stock Plunges as Vaccine Maker Slashes R&D Budget: What to Know

Moderna stock is plunging Thursday after the COVID-19 vaccine maker announced plans to drastically cut its R&D spending to focus on new product approvals.

Kiplinger

Read news from The Economist, FT, and more,
with one subscription

Is Moderna Stock Underperforming the Nasdaq?

While Moderna has underperformed the broader Nasdaq index in 2024, analysts are reasonably bullish about the stock's potential.

Barchart

Are Wall Street Analysts Predicting Moderna Stock Will Climb or Sink?

Moderna has underperformed many of its peers and the broader market YTD, but Wall Street analysts are optimistic about the stock’s prospects.

Barchart

Moderna's Quarterly Earnings Preview: What You Need to Know

Moderna is expected to release its fiscal second-quarter earnings next month, and analysts project a narrower loss.

Barchart

Is Moderna Stock Outperforming the S&P 500?

Moderna recently outperformed the S&P 500, and Wall Street analysts are moderately optimistic about the stock’s prospects.

Barchart

Is This Biotech Stock's OpenAI Partnership a Game-Changer?

With AI making waves in biotech, could this biotech’s OpenAI partnership be the catalyst for new highs?

Barchart

Is Wall Street Bullish or Bearish on Moderna Stock?

Moderna has outperformed many of its peers and the broader market YTD, but Wall Street analysts are cautiously optimistic about the stock's prospects.

Barchart

Biotech Investors: Should You Buy, Hold, or Sell Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR)?

Despite facing several challenges, the biotech sector thrives due to growing demand for effective treatments, consistent innovations, and a sustained demand for high-quality drugs and therapies. Let's assess whether one should Buy, Hold, or Sell biotech stocks Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR). Keep reading.

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Moderna (MRNA) Earnings Analysis: Buy or Watch for Gains?

Moderna’s (MRNA) mRNA platform is positioned to deliver significant long-term impact with its mRNA medicines, but declining sales amid plummeting demand for its COVID-19 vaccine, steep losses, and cash burn reflect uncertainty around its near-term prospects. As MRNA is set to release its fourth-quarter 2023 results this Thursday, let’s find…

StockNews.com

Moderna (MRNA) and Biogen (BIIB) - Are There Upsides Left in These Biotech Stocks?

Despite macroeconomic challenges, the biotech industry thrives on innovation, demand, adaptability, and technological advancements, demonstrating resilience. So, let’s analyze the upside potential of popular biotech stocks Biogen (BIIB) and Moderna (MRNA).

StockNews.com

Moderna (MRNA) vs. Exelixis (EXEL) - Which Biotech Stock Is Worth Buying?

The biotech industry is poised for long-term growth, supported by the advancements in personalized medicine and integration with information technology. While leading biotech stocks Moderna (MRNA) and Exelixis (EXEL) should benefit from the industry tailwinds, let us predict which stock is worth buying.

StockNews.com

Moderna (MRNA) and Acorda Therapeutics (ACOR): Buy, Hold, or Sell in 2024?

The biotech industry is growing as a result of steady demand and tech advancements. Therefore, let’s assess the prospects of biotech stocks Acorda Therapeutics (ACOR) and Moderna (MRNA). Read on.

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Moderna (MRNA) and 2 More Biotech Stocks That Are Worth Watching

Growing demand for personalized medicines and rising adoption of machine learning tools are expected to boost the biotech industry. Therefore, it could be wise to watch fundamentally strong biotech stocks Moderna (MRNA), Amicus Therapeutics (FOLD), and Entrada Therapeutics (TRDA). Read more.

Barchart

Bearish Outlook? Try These Bear Call Spread Trades

A bear call spread is a type of vertical spread, meaning that two options within the same expiry month are being traded.

StockNews.com

Moderna (MRNA) Stock Analysis: Is the Biotech Stock a Buy at This Time?

Biotech company Moderna (MRNA) recently published positive data from its latest flu vaccine trial, garnering investors’ attention. While the company focusing on expanding its product portfolio, is this the right time to invest in its stock? Keep reading.

Barchart

This Biotech Stock Offers Innovative Growth at a Massive Discount

Moderna stock continues to sag, even as new COVID variants emerge. However, investors may be underestimating the potential of the mRNA pipeline.

StockNews.com

Which of These 3 Biotech Stocks Are a Buy, Sell, or Hold?

Advanced medical technologies and the pivotal role of technology in drug development are poised to drive significant growth in the biotech industry. Against this backdrop, should you buy, sell or hold biotech stocks Moderna (MRNA), MacroGenics (MGNX), and Amicus Therapeutics (FOLD)? Let’s find out….

StockNews.com

Is Now the Time to Buy Into Moderna, Inc. (MRNA)?

Is now the time to invest in Moderna (MRNA) after the company revealed that its updated vaccines would be effective against two new COVID-19 subvariants? Let’s look at its financial metrics to gauge its prospects….

StockNews.com

Moderna (MRNA) vs. Amicus Therapeutics (FOLD): Which Biotech Stock Should You Add to Your Portfolio?

Healthcare is considered a reliable defensive sector. So, amid the current uncertain economic landscape, let's determine the more favorable investment option between two prominent pharmaceutical companies, Moderna (MRNA) and Amicus Therapeutics (FOLD). Keep reading.

1 2 3 4 5

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.